OBJECTIVE: To assess the efficacy and side effects of @entity1140 in the management of @entity1 with high-risk corneal and limbal grafts. DESIGN: Noncomparative case series. @entity1 : Seventeen @entity1 (23 grafts) were treated with @entity1140 ; 15 @entity1 (20 host corneas) had two or more quadrants of stromal vascularization, 6 @entity1 had stem cell deficiency, and 6 @entity1 had @entity726 . Seven @entity1 had received one previous graft, six @entity1 had two previous grafts, and four @entity1 had three previous grafts. INTERVENTION: @entity1 with high-risk corneal and limbal grafts were treated with systemic @entity1140 at a mean optimum dosage of 4.4 mg daily (range, 2-12 mg daily). MAIN OUTCOME MEASURES: Graft survival, visual acuity. RESULTS: No @entity1 has had irreversible graft rejection while receiving @entity1140 . The follow-up period ranges from 12 to 46 months, with a mean of 24 months. Three @entity1 have had reversible graft rejection associated with low @entity1140 levels. Nine @entity1 have stopped treatment; two had reversible rejection within 2 months of stopping, and five grafts remain clear. The other four @entity1 stopped treatment because of graft failure, which was not considered to be rejection related. Eight @entity1 remain on treatment, and all have clear grafts. CONCLUSIONS: @entity1140 ( @entity1140 ) is effective in prevention of rejection in @entity1 with high-risk corneal and limbal grafts.

@entity1140 ( XXXX ) in the management of high-risk corneal and limbal grafts.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PARTICIPANTS'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['FK506', 'Tacrolimus', 'tacrolimus']
@entity1140 :: (MESH:D016559,Chemical) :: ['FK506']
